12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

QPI-1007: Phase I data

Interim data from an open-label, dose-escalation, international Phase I trial in 38 patients showed a single injection of QPI-1007 had no dose limiting toxicities up to and including the highest dose of 6 mg. The first portion of the trial was a single-dose escalation safety study in patients who were legally...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >